Study reveals how to keep Alzheimer's blood tests reliable before analysis

Researchers have identified how plasma biomarkers for Alzheimer's disease break down during sample handling, a critical finding for the emerging blood-test diagnostics industry. The results could improve accuracy of early-detection tests that diagnostic companies are racing to commercialize, potentially affecting screening protocols and clinical trial reliability worth billions in market value.

Originaltitel: Preanalytical stability of plasma biomarkers for Alzheimer's disease pathology